A new daily pill called orforglipron could offer an easier alternative to injections for weight loss, with trial results showing that one in five patients lost 20% or more of their body weight over 72 weeks.
Developed by Eli Lilly, the pill acts on GLP-1 receptors, the same mechanism as popular jabs like Wegovy and Mounjaro, but in a tablet form that is easier to store, distribute, and take. In a study of more than 3,000 adults with obesity but no diabetes, patients on the highest dose lost an average of 11.2% of their body weight, while nearly 55% shed at least 10%.
Researchers also reported improvements in blood pressure, waist size, and cholesterol. The most common side effects were mild to moderate stomach issues.
Experts say orforglipron could expand access to effective obesity treatments by offering a cheaper, more convenient option than injections. The pill is not yet approved by regulators, but Eli Lilly expects high demand once it is launched.
